Overall, a proportion between 15% and 20% of all GCs is deemed to express HER2; however, a key element to consider when discussing HER2 assessment is the high degree of intratumoral heterogeneity in GC compared to other solid tumors such as breast cancer [10]. Here, ERBB2 is linked to breast cancer.